- The European Medicines Agency (EMA) expects to decide on the authorization for Pfizer Inc PFE / BioNTech SE BNTX COVID-19 booster shot at the beginning of October, Reuters reported citing a source directly familiar with the matter.
- The European decision will follow the FDA authorization granted for the additional dose of the vaccine for certain populations.
- Related Content: Pfizer COVID-19 Vaccine Booster Shot Approved By FDA For High-Risk Individuals, People 65 And Up.
- "EMA's decision on the third dose of Pfizer is expected for the beginning of October," Reuters reported quoting the source who stayed anonymous because of the sensitivity of the matter.
- Many EU nations have already decided to administer booster COVID-19 shots despite facing higher legal risks without a formal decision by the EMA.
- Related Content: EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters.
- Pfizer and BioNTech have signed three deals to deliver 2.4 billion vaccine doses to the EU.
- The latest deal covers 900 million doses, with a significant portion likely necessary if booster shots are needed.
- Moderna Inc MRNA made regulatory submissions to the EMA seeking conditional marketing approval for its COVID-19 booster shot early this month.
- Related Content: After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose.
- Price Action: PFE stock is up 1.18% at $44.47, while BNTX stock is up 3.66% at $351.84 during the market session on the last check Thursday.
- Photo by Johaehn from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
